SNX1 and ovarian cancer: In this study, we revealed that SNX1 is significantly downregulated in ovarian cancer and correlates with poor prognosis and reduced sensitivity to chemotherapeutic agents such as paclitaxel, docetaxel, and 5-fluorouracil.